Nature Reviews Drug Discovery
IF
84.69
Papers
4,147
Papers 4,474
1 page of 448 pages (4,474 results)
Newest
Source
The NIH and FDA’s newly launched 27-member public–private partnership will spend US76 million addressing the hurdles of AAV-based gene therapies for ultra-rare diseases. The NIH and FDA’s newly launched 27-member public–private partnership will spend US6 million addressing the hurdles of AAV-based gene therapies for ultra-rare diseases.
Source
Susan Galbraith, head of Oncology Research & Development at AstraZeneca, discusses the opportunities oncologists can’t walk away from, including HER2, antibody–drug conjugates and earlier intervention. null Susan Galbraith, head of Oncology Research & Development at AstraZeneca, discusses the opportunities oncologists can’t walk away from, including HER2, antibody–drug conjugates and earlier intervention.
Source
#1Dean G. BrownH-Index: 21
#2Heike J. WobstH-Index: 9
Last. Noel SouthallH-Index: 44
view all 5 authors...
Source
Source
Source
Source
Source
Source
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.